<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation of the adult patient with hepatic granuloma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation of the adult patient with hepatic granuloma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation of the adult patient with hepatic granuloma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven Flamm, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Granulomas are circumscribed lesions of mainly mononuclear cells that develop in response to antigenic stimuli. Hepatic granulomas may be found incidentally on an otherwise normal liver biopsy or may be caused by systemic diseases (eg, infection, autoimmune disease). Although the granulomas alone rarely affect liver function, it is important to identify an underlying systemic disease since it may have prognostic and therapeutic implications. The initial evaluation typically includes patient history, physical examination, laboratory studies, and granuloma classification based on morphology.</p><p>This topic will discuss the evaluation and causes of hepatic granulomas. The diagnosis and management of drug-induced liver injury are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">"Drug-induced liver injury"</a>.)</p><p>The approach to the patient with a solid liver lesion is presented separately. (See  <a class="medical medical_review" href="/z/d/html/3575.html" rel="external">"Approach to the adult patient with an incidental solid liver lesion"</a>.)</p><p>The diagnosis and management of cystic liver lesions are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3588.html" rel="external">"Diagnosis and management of cystic lesions of the liver"</a>.)</p><p>Evaluation of the patient with hepatomegaly is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/89223.html" rel="external">"Overview of the evaluation of hepatomegaly in adults"</a>.)</p><p class="headingAnchor" id="H2863617188"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Hepatic granulomas are found in approximately 2 to 10 percent of patients who undergo liver biopsy, and one or two isolated granulomas are not typically associated with a symptomatic disease process [<a href="#rid1">1,2</a>]. </p><p>The most common causes of hepatic granuloma in the United States are sarcoidosis, mycobacterial infection (eg, <em>Mycobacterium tuberculosis</em>), primary biliary cholangitis, and drug-induced liver injury [<a href="#rid2">2</a>]. (See <a class="local">'Causes'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOLOGIC FEATURES</span><span class="headingEndMark"> — </span>A granuloma is a circumscribed lesion that forms as a result of an inflammatory reaction in body tissues. It is characterized by a central accumulation of mononuclear cells, primarily macrophages, with a surrounding rim consisting of lymphocytes and fibroblasts. The lesions are distinct from nearby uninvolved tissue  (<a class="graphic graphic_picture graphicRef64126" href="/z/d/graphic/64126.html" rel="external">picture 1</a>).</p><p>Early in the development of the granuloma, lesions may appear as punched-out clusters of histiocytes or lymphocytes. The granulomas evolve with stimulation of mononuclear cells from a variety of cytokines. Activated macrophages are transformed to resemble epithelial cells (referred to as epithelioid cells), which characteristically have abundant, pale cytoplasm. Adjacent macrophages may fuse, forming multinucleated giant cells. Granulomas infiltrated by eosinophils are suggestive of a drug reaction or parasitic infection. (See <a class="local">'Causes'</a> below.)</p><p>The cells within the granuloma are capable of secreting a variety of proteins. As an example, epithelioid cells from patients with sarcoidosis secrete lysozyme, collagenase, and angiotensin converting enzyme (ACE). Serologic markers of sarcoidosis including ACE are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a>.)</p><p>Granuloma morphology and histology of the liver parenchyma surrounding the granuloma may be helpful for determining the etiology, and this is discussed below. (See <a class="local">'Initial evaluation'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">CAUSES</span><span class="headingEndMark"> — </span>Granulomas in the liver are associated with infectious and noninfectious causes; however, for some patients, a cause cannot be identified despite diagnostic evaluation including laboratory studies and liver histology [<a href="#rid1">1,3</a>]. In a study including 442 liver biopsies with granulomatous lesions, the most common causes were primary biliary cholangitis (215 cases [49 percent]) and sarcoidosis (37 cases [8 percent]), while an infectious pathogen (eg, <em>Mycobacterium tuberculosis</em>) was found in 15 cases (3 percent) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Infectious causes</span><span class="headingEndMark"> — </span>Infectious causes of hepatic granuloma include those related to bacterial, fungal, parasitic, and viral infections: </p><p class="bulletIndent1"><span class="glyph">●</span><em>Mycobacterium tuberculosis</em> – Most patients with mycobacterial infections with hematogenous spread (miliary tuberculosis) have hepatic granuloma; in addition, liver involvement may occur in patients with localized extrapulmonary tuberculosis and/or with pulmonary tuberculosis [<a href="#rid3">3,4</a>]. Patients may present with fever, fatigue, anorexia, hepatomegaly, right upper quadrant pain, or they may be asymptomatic [<a href="#rid5">5</a>]. Serum aminotransferases may be minimally elevated, but jaundice is rare. Granulomas are characteristically found in the portal areas and are caseating [<a href="#rid3">3</a>]. With special stains, acid-fast bacilli can occasionally be seen within the granulomas on the liver biopsy specimen. (See  <a class="medical medical_review" href="/z/d/html/8024.html" rel="external">"Clinical manifestations, diagnosis, and treatment of miliary tuberculosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fungal diseases – Fungal infections with liver involvement typically occur in the setting of disseminated disease in immunocompromised patients. Infected patients may have abdominal pain, hepatomegaly, and abnormal liver biochemical tests. Fungal infections associated with hepatic granulomas include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Histoplasmosis: Most cases of histoplasmosis in the United States are acquired in the midwestern and central part of the country [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/2455.html" rel="external">"Pathogenesis and clinical manifestations of disseminated histoplasmosis"</a> and  <a class="medical medical_review" href="/z/d/html/2461.html" rel="external">"Diagnosis and treatment of disseminated histoplasmosis in patients without HIV"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Coccidioidomycosis: Most cases of coccidioidomycosis in the United States are acquired in the southwestern part of the country. (See  <a class="medical medical_review" href="/z/d/html/2449.html" rel="external">"Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis"</a> and  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Candidiasis: Patients with hepatic candidiasis typically have a liver biopsy specimen showing granulomatous inflammatory reaction with necrotic central areas [<a href="#rid5">5,7</a>]. (See  <a class="medical medical_review" href="/z/d/html/2425.html" rel="external">"Chronic disseminated candidiasis (hepatosplenic candidiasis)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Q fever – Q fever is caused by exposure to <em>Coxiella burnetii</em>, a rickettsial agent that infects cows, goats, and sheep. Organisms may be inhaled, ingested, or acquired through tick bites. Acute infection may include flu-like illness (eg, fever, headache), pneumonia, and hepatitis. Patients with liver involvement may present with hepatomegaly and transaminitis, and liver biopsy may demonstrate granuloma with a ring of fibrinoid necrosis surrounded by lymphocytes and histiocytes (fibrin-ring granuloma) [<a href="#rid8">8,9</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Brucellosis – Brucellosis (also called undulant, Mediterranean, or Malta fever) is a zoonotic infection transmitted to humans from infected animals (eg cattle, sheep, goats, pigs) by ingestion of food products (unpasteurized dairy products) or by occupational exposure. Symptoms include fever, malaise, sweats, and arthralgias. The onset of symptoms of brucellosis may be abrupt or insidious, developing over several days to weeks. Symptoms can last for months with periods in which patients feel relatively well (hence the name "undulant" fever). Physical findings, when present, are usually limited to minimal lymphadenopathy and occasionally hepatosplenomegaly [<a href="#rid10">10</a>]. Liver biopsy may demonstrate noncaseating granulomas in patients infected with <em>Brucella abortus</em> and <em>Brucella melitensis</em> [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent1">The clinical manifestations, diagnosis, and treatment of brucellosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3140.html" rel="external">"Brucellosis: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/121314.html" rel="external">"Brucellosis: Treatment and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV infection – Patients with untreated HIV infection are at risk for several opportunistic infections that have been associated with hepatic granulomas. Examples of opportunistic infections affecting patients with reduced cell-mediated immunity include <em>Mycobacterium tuberculosis,</em> <em>Mycobacterium avium</em> complex (MAC), and toxoplasmosis. (See  <a class="medical medical_review" href="/z/d/html/3747.html" rel="external">"Overview of prevention of opportunistic infections in patients with HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other infections – Parasitic infections associated with hepatic granuloma include schistosomiasis [<a href="#rid12">12,13</a>], visceral leishmaniasis [<a href="#rid14">14</a>], and rarely, <em>Enterobius vermicularis</em> (pinworm) [<a href="#rid15">15</a>] or toxoplasmosis. </p><p></p><p class="bulletIndent1">Hepatic granulomas infrequently occur in patients with viral infections, but have been associated with Epstein-Barr virus (EBV), cytomegalovirus, chronic hepatitis B virus, and hepatitis C virus infections [<a href="#rid3">3,16-19</a>].</p><p></p><p class="headingAnchor" id="H2985337549"><span class="h2">Noninfectious causes</span></p><p class="headingAnchor" id="H1303656859"><span class="h3">Sarcoidosis</span><span class="headingEndMark"> — </span>Sarcoidosis is a systemic granulomatous disease of unknown etiology characterized by the formation of nonnecrotizing (ie, noncaseating) granulomas. Most patients are asymptomatic and have only liver biochemical abnormalities (eg, elevated alkaline phosphatase and gamma-glutamyl transpeptidase) [<a href="#rid20">20,21</a>]. Patients with hepatic granulomas and sarcoidosis rarely develop chronic liver disease such as chronic cholestasis, cirrhosis, and/or portal hypertension. (See  <a class="medical medical_review" href="/z/d/html/4317.html" rel="external">"Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis", section on 'Hepatic'</a>.)</p><p>While sarcoid granulomas are often located in the portal tract, there are no specific laboratory or histopathologic findings that can establish the diagnosis of hepatic sarcoidosis. Thus, for patients with suspected sarcoidosis, additional evaluation for other possible causes of hepatic granuloma (eg, infection) is typically performed. The clinical manifestations and diagnosis of pulmonary sarcoidosis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a>.)</p><p>Management of patients with hepatic sarcoidosis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4317.html" rel="external">"Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H365724255"><span class="h3">Autoimmune disorders</span><span class="headingEndMark"> — </span>Autoimmune disorders associated with hepatic granuloma include:</p><p class="bulletIndent1"><span class="glyph">●</span>Primary biliary cholangitis – Primary biliary cholangitis (PBC) is characterized by an ongoing immunologic attack on the intralobular bile ducts that results in cholestasis and may eventually lead to cirrhosis and liver failure. PBC is rare, and most patients are women who are diagnosed between 30 and 65 years of age and who have elevated alkaline phosphatase levels and positive antimitochondrial antibodies. The clinical manifestations and diagnosis of PBC are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3621.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other autoimmune disorders – Hepatic granulomas have been reported in patients with granulomatosis with polyangiitis [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H1470175697"><span class="h3">Drug-induced liver injury</span><span class="headingEndMark"> — </span>Adverse drug reactions have been associated with hepatic granulomas, and drugs most commonly implicated are <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>, sulfa drugs, and <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>  (<a class="graphic graphic_table graphicRef56830" href="/z/d/graphic/56830.html" rel="external">table 1</a>) [<a href="#rid3">3</a>]. For patients with drug-induced liver injury, liver biopsy findings typically include hepatocellular injury and/or cholestatic changes. (See  <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">"Drug-induced liver injury"</a>.) </p><p>Granulomatous hepatitis is a rare complication of <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical Bacillus Calmette-Guerin</a> (BCG) therapy in patients with bladder cancer. (See  <a class="medical medical_review" href="/z/d/html/2973.html" rel="external">"Infectious complications of intravesical BCG immunotherapy"</a>.)</p><p>Fibrin-ring granulomas have been reported with some drug reactions including <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> and immune checkpoint inhibitors [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/134862.html" rel="external">"Hepatic, pancreatic, and rare gastrointestinal complications of immune checkpoint inhibitor therapy", section on 'What is the role of liver biopsy?'</a>.)</p><p class="headingAnchor" id="H3885891866"><span class="h3">Idiopathic</span><span class="headingEndMark"> — </span>The etiology of hepatic granulomas for some symptomatic patients may remain uncertain despite diagnostic evaluation. The exact proportion of hepatic granulomas of uncertain etiology is unknown but is probably in the range of 10 to 35 percent [<a href="#rid1">1</a>]. The term "idiopathic granulomatous hepatitis" refers to a syndrome characterized by a nonacute febrile illness, myalgias, hepatosplenomegaly, and arthralgias of unclear etiology in patients with hepatic granulomas [<a href="#rid24">24</a>]. Laboratory findings are nonspecific and may include elevated inflammatory markers (eg, C-reactive protein). (See <a class="local">'Patients with nondiagnostic testing'</a> below.)</p><p class="headingAnchor" id="H4214441893"><span class="h3">Other causes</span><span class="headingEndMark"> — </span>Other conditions associated with hepatic granuloma include:</p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy – Hodgkin lymphoma, and to a lesser extent non-Hodgkin lymphoma, have been associated with hepatic granulomas [<a href="#rid25">25,26</a>]. Areas of the liver that are affected by granuloma formation may or may not have involvement of the lymphoma. The presence of granulomas does not influence staging of Hodgkin lymphoma. (See  <a class="medical medical_review" href="/z/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Foreign body granulomatosis – Patients with talc (hydrous magnesium silicate) pulmonary granulomatosis may also have liver involvement, and this is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4370.html" rel="external">"Foreign body granulomatosis"</a>.)</p><p></p><p class="headingAnchor" id="H869881436"><span class="h1">INITIAL EVALUATION</span></p><p class="headingAnchor" id="H3836926360"><span class="h2">When is further evaluation indicated?</span><span class="headingEndMark"> — </span>For patients with hepatic granuloma, the need for additional testing depends on whether the underlying cause can be identified based on the patient's history and/or initial testing (eg, liver biopsy). For example, further diagnostic testing is indicated for:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic patients with hepatic granuloma of unknown etiology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic patients with a suspected etiology based on initial testing (eg, hepatic granulomas on thoracic computed tomography [CT] in a patient with known or suspected pulmonary sarcoidosis). Further testing is performed to confirm the etiology of the granuloma and exclude other causes (eg, infections). (See  <a class="medical medical_review" href="/z/d/html/4317.html" rel="external">"Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis", section on 'Hepatic'</a>.)</p><p></p><p>For patients with suspected systemic or pulmonary infection (eg, tuberculosis), an expedited evaluation is performed, and the diagnostic evaluation for patients with tuberculosis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p>However, further testing is not typically performed for:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with known liver disease that is associated with hepatic granuloma (eg, primary biliary cholangitis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who undergo liver biopsy that demonstrated granuloma(s) and also identified the underlying disease (eg, hepatic candidiasis) (see  <a class="medical medical_review" href="/z/d/html/2425.html" rel="external">"Chronic disseminated candidiasis (hepatosplenic candidiasis)", section on 'Diagnosis'</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are asymptomatic (ie, no symptoms suggestive of systemic or hepatobiliary disease) and have normal liver biochemistries (see <a class="local">'Clinical presentation'</a> below)</p><p></p><p class="headingAnchor" id="H2555266409"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>The patient's clinical presentation and history may help narrow the list of possible causes of granuloma and includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms of systemic disease (eg, fever, sweats, anorexia, weight loss)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms and signs of hepatobiliary disease (eg, abdominal pain, jaundice, pruritus)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for exposure to potential hepatotoxins (eg, medications)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for exposure to infectious agents (eg, patients living in or returning from endemic areas) (see <a class="local">'Infectious causes'</a> above and  <a class="medical medical_review" href="/z/d/html/3888.html" rel="external">"Evaluation of fever in the returning traveler"</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for opportunistic infection (eg, use of immunosuppressive medications, HIV infection)</p><p></p><p>The clinical presentation of hepatic granuloma includes a spectrum from asymptomatic patients with an incidental finding on an otherwise normal liver biopsy specimen to patients who are symptomatic from underlying systemic or hepatobiliary disease (eg, infection, drug-induced liver injury, primary biliary cholangitis) [<a href="#rid16">16</a>]. The granuloma itself does not typically produce any symptoms, whereas the clinical features reflect the underlying disease and its severity. For example, systemic symptoms such as fever, sweats, and weight loss may be seen in patients with tuberculosis or other infectious causes. Liver fibrosis with portal hypertension and cirrhosis is uncommon but may be seen in patients with primary biliary cholangitis and schistosomiasis.</p><p class="headingAnchor" id="H51048756"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>For patients with hepatic granuloma, physical examination includes assessment of:</p><p class="bulletIndent1"><span class="glyph">●</span>Liver size and consistency (see  <a class="medical medical_review" href="/z/d/html/89223.html" rel="external">"Overview of the evaluation of hepatomegaly in adults", section on 'Examining the liver'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spleen size</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal distension and ascites</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stigmata of chronic liver disease (eg, spider angiomata) (see  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis"</a>)</p><p></p><p class="headingAnchor" id="H980887670"><span class="h2">Laboratory and imaging studies</span><span class="headingEndMark"> — </span>Laboratory testing is performed to look for abnormalities in liver biochemistries or function and to contribute to the infectious work up. For most patients, we obtain the following tests (or review testing that had been obtained previously):</p><p class="bulletIndent1"><span class="glyph">●</span>Serum aminotransferases: alanine aminotransferase (ALT) and aspartate aminotransferase (AST)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alkaline phosphatase</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Total bilirubin</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum albumin</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prothrombin time/international normalized ratio</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angiotensin-converting enzyme (ACE)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimitochondrial antibody</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interferon-gamma release assay (eg, QuantiFERON-TB Gold In-Tube assay) or <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ultrasound of the liver</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with respiratory symptoms or suspected pulmonary disease (eg, sarcoidosis), chest radiograph</p><p></p><p>Some patients with hepatic granuloma are asymptomatic but have laboratory abnormalities (eg, elevated serum aminotransferases and/or elevated alkaline phosphatase). Elevations in aminotransferases (ALT, AST) typically are not greater than two times the upper limit of normal. </p><p>Imaging including plain radiographs, liver ultrasound, computed tomography, and magnetic resonance imaging (MRI) may demonstrate calcification in chronic granulomas; however, imaging often does not establish the underlying cause [<a href="#rid27">27</a>]. </p><p class="headingAnchor" id="H410519817"><span class="h2">Role of liver biopsy</span><span class="headingEndMark"> — </span>The liver biopsy specimen is evaluated for characteristics of and possible cause for granuloma. Most patients with hepatic granulomas have undergone liver biopsy (ie, the granuloma was identified based on the biopsy specimen). For symptomatic patients with hepatic granuloma based on imaging alone and with elevated liver tests (eg, alkaline phosphatase), we typically obtain a liver biopsy as part of the evaluation. However, identifying hepatic granuloma on imaging alone in the absence of symptoms is uncommon. </p><p class="headingAnchor" id="H1975946014"><span class="h3">Histopathologic findings</span><span class="headingEndMark"> — </span>Examination of the liver biopsy specimen in patients with hepatic granuloma includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Culture and special staining for acid-fast bacilli, fungi, and other organisms. (See  <a class="medical medical_review" href="/z/d/html/8024.html" rel="external">"Clinical manifestations, diagnosis, and treatment of miliary tuberculosis", section on 'Diagnostic tools'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Visualizing with polarizing light microscopy (occasionally foreign body talc granulomas will be identified).</p><p></p><p>Granuloma morphology and location in addition to other liver biopsy findings may be helpful for determining the etiology  (<a class="graphic graphic_table graphicRef128522" href="/z/d/graphic/128522.html" rel="external">table 2</a>) [<a href="#rid1">1</a>] (see <a class="local">'Pathologic features'</a> above): </p><p class="bulletIndent1"><span class="glyph">●</span>Necrosis: Necrotic (caseating) granulomas are commonly associated with tuberculosis, whereas nonnecrotic (noncaseating) granulomas are often associated with sarcoidosis, and less commonly, with primary biliary cholangitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Location: Most granulomas occur in the liver parenchyma, while portal granulomas are often associated with specific diseases (eg, primary biliary cholangitis, sarcoidosis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver parenchyma surrounding the granuloma: The liver parenchyma surrounding the granuloma may suggest an underlying etiology (eg, lymphoma). (See <a class="local">'Other causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Microorganisms: In addition to the granulomatous reaction, fungal organisms or schistosome eggs may be seen in liver biopsy specimens.</p><p></p><p>Histopathologic examination of the liver and interpretation of liver biopsy specimens are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/15756.html" rel="external">"Interpretation of nontargeted liver biopsy findings in adults"</a>.)</p><p class="headingAnchor" id="H2775886456"><span class="h1">PATIENTS WITH NONDIAGNOSTIC TESTING</span></p><p class="headingAnchor" id="H2650384977"><span class="h2">Specialty consultation</span><span class="headingEndMark"> — </span>Consultation with a hepatology specialist is indicated for symptomatic patients with hepatic granuloma of uncertain etiology despite initial evaluation.</p><p class="headingAnchor" id="H4104589770"><span class="h2">Patients with suspected tuberculosis</span><span class="headingEndMark"> — </span>For patients with hepatic granuloma in whom a diagnosis of tuberculosis is suspected but not confirmed (ie, patients with fever, sweats), consultation with an infectious disease specialist is indicated for further evaluation and for consideration of antituberculosis therapy. (See <a class="local">'Initial evaluation'</a> above and <a class="local">'Infectious causes'</a> above.)</p><p>Antibiotic therapy for tuberculosis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8024.html" rel="external">"Clinical manifestations, diagnosis, and treatment of miliary tuberculosis"</a>.)</p><p>The rationale for this approach is that some patients initially diagnosed with idiopathic granulomatous hepatitis have been subsequently diagnosed with an underlying infection such as tuberculosis. Treatment with immunosuppressive medications such as <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> may result in more severe infection. (See  <a class="medical medical_review" href="/z/d/html/8029.html" rel="external">"Epidemiology and pathology of miliary and extrapulmonary tuberculosis"</a> and <a class="local">'Idiopathic granulomatous hepatitis'</a> below.)</p><p class="headingAnchor" id="H1194956581"><span class="h2">Idiopathic granulomatous hepatitis</span></p><p class="headingAnchor" id="H2185618550"><span class="h3">Initial management</span><span class="headingEndMark"> — </span>For some symptomatic patients, the etiology of hepatic granuloma may remain uncertain despite diagnostic evaluation, and this condition is termed idiopathic granulomatous hepatitis [<a href="#rid28">28-30</a>]. (See <a class="local">'Idiopathic'</a> above.)</p><p>For such patients, we begin a course of oral glucocorticoid therapy (eg, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 20 to 40 mg daily). Patients treated with glucocorticoids typically have rapid symptomatic improvement (ie within a few days), while elevated liver biochemistries resolve within several months. For patients with symptomatic improvement, the prednisone dose is gradually tapered over four to eight weeks. (See  <a class="medical medical_review" href="/z/d/html/124.html" rel="external">"Pharmacologic use of glucocorticoids"</a>.) </p><p>For patients who respond to oral glucocorticoids, the long-term prognosis is good, although relapse of symptoms (eg, fever, myalgias) after discontinuing glucocorticoids is not uncommon. Thus, patients who develop recurrent symptoms after completing the initial course of glucocorticoids are typically given a second course of glucocorticoids for four to eight weeks. </p><p>Evidence supporting the use of glucocorticoids for idiopathic granulomatous hepatitis are limited to case reports and small case series [<a href="#rid31">31-33</a>].</p><p class="headingAnchor" id="H1109696972"><span class="h3">Subsequent therapy</span><span class="headingEndMark"> — </span>For patients who do not respond or cannot tolerate glucocorticoids, data from case reports and small case series suggested that possible therapeutic alternatives include <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid34">34</a>] and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid35">35</a>]. For example, in a case series of seven patients with idiopathic granulomatous hepatitis who were treated with methotrexate, fever resolved in all seven patients within three months, while fatigue and anorexia improved in six patients (86 percent). In addition, granulomas resolved in four patients in whom a liver biopsy was repeated.</p><p class="headingAnchor" id="H2922118475"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122574.html" rel="external">"Society guideline links: Focal liver lesions"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic granulomas are found in approximately 2 to 10 percent of patients who undergo liver biopsy, and one or two granulomas in the setting of otherwise normal liver histology are not typically associated with a symptomatic disease process. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A granuloma is a circumscribed lesion that forms as a result of an inflammatory reaction in body tissues. It is characterized by a central accumulation of mononuclear cells, primarily macrophages, with a surrounding rim consisting of lymphocytes and fibroblasts  (<a class="graphic graphic_picture graphicRef64126" href="/z/d/graphic/64126.html" rel="external">picture 1</a>). (See <a class="local">'Pathologic features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic granulomas are associated with infectious and noninfectious causes. The most common causes of hepatic granuloma in the United Sates are sarcoidosis, mycobacterial infection, primary biliary cholangitis, and drug-induced liver injury. (See <a class="local">'Causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical presentation of hepatic granuloma includes a spectrum from asymptomatic patients with an incidental finding on otherwise normal liver biopsy specimen to patients who are symptomatic from underlying systemic or hepatobiliary disease. The granuloma itself does not typically produce any symptoms, whereas the clinical features reflect the underlying disease and its severity. (See <a class="local">'Clinical presentation'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For symptomatic patients with hepatic granuloma, the initial evaluation includes obtaining a history to identify symptoms of and risk factors for underlying disease, performing a physical examination, and obtaining diagnostic studies including liver biochemical tests, angiotensin-converting enzyme (ACE) level, and antimitochondrial antibody, interferon-gamma release assay, and liver ultrasound. For patients with respiratory symptoms or suspected pulmonary disease (eg, sarcoidosis), chest radiograph is also obtained. (See <a class="local">'Initial evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The liver biopsy specimen is evaluated for characteristics of and possible cause for the granuloma(s)  (<a class="graphic graphic_table graphicRef128522" href="/z/d/graphic/128522.html" rel="external">table 2</a>). Most patients with hepatic granulomas have undergone liver biopsy (ie, the granuloma was identified based on the biopsy specimen). For symptomatic patients with hepatic granuloma based on imaging alone and with elevated liver tests (eg, alkaline phosphatase), we typically obtain a liver biopsy as part of the evaluation. (See <a class="local">'Role of liver biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For symptomatic patients with hepatic granuloma of uncertain etiology despite diagnostic evaluation, our approach to management includes (see <a class="local">'Patients with nondiagnostic testing'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with suspected tuberculosis, an infectious disease consultation is obtained for consideration of antituberculosis therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients without suspected tuberculosis, we suggest a course of oral glucocorticoid therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically use <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 20 to 40 mg daily and gradually taper the dose over four to eight weeks. </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Drebber U, Kasper HU, Ratering J, et al. Hepatic granulomas: histological and molecular pathological approach to differential diagnosis--a study of 442 cases. Liver Int 2008; 28:828.</a></li><li><a class="nounderline abstract_t">Lagana SM, Moreira RK, Lefkowitch JH. Hepatic granulomas: pathogenesis and differential diagnosis. Clin Liver Dis 2010; 14:605.</a></li><li><a class="nounderline abstract_t">Choi EK, Lamps LW. Granulomas in the Liver, with a Focus on Infectious Causes. Surg Pathol Clin 2018; 11:231.</a></li><li><a class="nounderline abstract_t">Flamm SL. Granulomatous liver disease. Clin Liver Dis 2012; 16:387.</a></li><li><a class="nounderline abstract_t">Lamps LW. Hepatic Granulomas: A Review With Emphasis on Infectious Causes. Arch Pathol Lab Med 2015; 139:867.</a></li><li><a class="nounderline abstract_t">Lamps LW, Molina CP, West AB, et al. The pathologic spectrum of gastrointestinal and hepatic histoplasmosis. Am J Clin Pathol 2000; 113:64.</a></li><li><a class="nounderline abstract_t">Johnson TL, Barnett JL, Appelman HD, Nostrant T. Candida hepatitis. Histopathologic diagnosis. Am J Surg Pathol 1988; 12:716.</a></li><li><a class="nounderline abstract_t">Fournier PE, Marrie TJ, Raoult D. Diagnosis of Q fever. J Clin Microbiol 1998; 36:1823.</a></li><li><a class="nounderline abstract_t">Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. MMWR Recomm Rep 2013; 62:1.</a></li><li><a class="nounderline abstract_t">Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med 2005; 352:2325.</a></li><li><a class="nounderline abstract_t">Akritidis N, Tzivras M, Delladetsima I, et al. The liver in brucellosis. Clin Gastroenterol Hepatol 2007; 5:1109.</a></li><li><a class="nounderline abstract_t">Hams E, Aviello G, Fallon PG. The schistosoma granuloma: friend or foe? Front Immunol 2013; 4:89.</a></li><li><a class="nounderline abstract_t">Shaker Y, Samy N, Ashour E. Hepatobiliary Schistosomiasis. J Clin Transl Hepatol 2014; 2:212.</a></li><li><a class="nounderline abstract_t">Moreno A, Marazuela M, Yebra M, et al. Hepatic fibrin-ring granulomas in visceral leishmaniasis. Gastroenterology 1988; 95:1123.</a></li><li><a class="nounderline abstract_t">Daly JJ, Baker GF. Pinworm granuloma of the liver. Am J Trop Med Hyg 1984; 33:62.</a></li><li><a class="nounderline abstract_t">Tahan V, Ozaras R, Lacevic N, et al. Prevalence of hepatic granulomas in chronic hepatitis B. Dig Dis Sci 2004; 49:1575.</a></li><li><a class="nounderline abstract_t">Ozaras R, Tahan V, Mert A, et al. The prevalence of hepatic granulomas in chronic hepatitis C. J Clin Gastroenterol 2004; 38:449.</a></li><li><a class="nounderline abstract_t">Nenert M, Mavier P, Dubuc N, et al. Epstein-Barr virus infection and hepatic fibrin-ring granulomas. Hum Pathol 1988; 19:608.</a></li><li><a class="nounderline abstract_t">Lobdell DH. 'Ring' granulomas in cytomegalovirus hepatitis. Arch Pathol Lab Med 1987; 111:881.</a></li><li><a class="nounderline abstract_t">Watanabe T, Jodo S. Hepatic sarcoidosis. CMAJ 2018; 190:E988.</a></li><li><a class="nounderline abstract_t">Kumar M, Herrera JL. Sarcoidosis and the Liver. Clin Liver Dis 2019; 23:331.</a></li><li><a class="nounderline abstract_t">Holl-Ulrich K, Klass M. Wegener s granulomatosis with granulomatous liver involvement. Clin Exp Rheumatol 2010; 28:88.</a></li><li><a class="nounderline abstract_t">Everett J, Srivastava A, Misdraji J. Fibrin Ring Granulomas in Checkpoint Inhibitor-induced Hepatitis. Am J Surg Pathol 2017; 41:134.</a></li><li><a class="nounderline abstract_t">Simon HB, Wolff SM. Granulomatous hepatitis and prolonged fever of unknown origin: a study of 13 patients. Medicine (Baltimore) 1973; 52:1.</a></li><li><a class="nounderline abstract_t">Kadin ME, Donaldson SS, Dorfman RF. Isolated granulomas in Hodgkin's disease. N Engl J Med 1970; 283:859.</a></li><li><a class="nounderline abstract_t">Braylan RC, Long JC, Jaffe ES, et al. Malignant lymphoma obscured by concomitant extensive epithelioid granulomas: report of three cases with similar clinicopathologic features. Cancer 1977; 39:1146.</a></li><li class="breakAll">Ros PR.. Diseases of the Abdomen and Pelvis 2018-2021: Diagnostic Imaging - IDKD Book, Hodler J, Kubik-Huch RA, von Schulthess GK. (Eds), Springer, Cham (CH) 2018.</li><li><a class="nounderline abstract_t">Sartin JS, Walker RC. Granulomatous hepatitis: a retrospective review of 88 cases at the Mayo Clinic. Mayo Clin Proc 1991; 66:914.</a></li><li><a class="nounderline abstract_t">Tofteland ND, Nassif II. Abnormal liver enzymes in a patient with Crohn's disease, psoriatic arthritis, and recurrent pancreatitis. Answer to the clinical challenges and images in GI question: image 5: Idiopathic granulomatous hepatitis. Gastroenterology 2010; 139:e14.</a></li><li><a class="nounderline abstract_t">Patedakis Litvinov BI, Pathak AP. Granulomatous hepatitis in a patient with Crohn's disease and cholestasis. BMJ Case Rep 2017; 2017.</a></li><li><a class="nounderline abstract_t">Lee YH, Choi CH, Lee NS, et al. Idiopathic granulomatous hepatitis manifested with fever of unknown origin. Korean J Intern Med 1996; 11:161.</a></li><li><a class="nounderline abstract_t">Zoutman DE, Ralph ED, Frei JV. Granulomatous hepatitis and fever of unknown origin. An 11-year experience of 23 cases with three years' follow-up. J Clin Gastroenterol 1991; 13:69.</a></li><li><a class="nounderline abstract_t">Penchas S, Ligumski M, Eliakim M. Idiopathic granulomatous hepatitis with a prolonged course: effect of corticosteroid therapy. Digestion 1978; 17:46.</a></li><li><a class="nounderline abstract_t">Wilson PA, Gan L, King S. Granulomatous hepatitis with hepatic mass lesions and a response to infliximab. Intern Med J 2015; 45:783.</a></li><li><a class="nounderline abstract_t">Knox TA, Kaplan MM, Gelfand JA, Wolff SM. Methotrexate treatment of idiopathic granulomatous hepatitis. Ann Intern Med 1995; 122:592.</a></li></ol></div><div id="topicVersionRevision">Topic 3582 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18312287" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hepatic granulomas: histological and molecular pathological approach to differential diagnosis--a study of 442 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21055685" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hepatic granulomas: pathogenesis and differential diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29751872" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Granulomas in the Liver, with a Focus on Infectious Causes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22541705" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Granulomatous liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26125427" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hepatic Granulomas: A Review With Emphasis on Infectious Causes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10631859" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The pathologic spectrum of gastrointestinal and hepatic histoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3414894" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Candida hepatitis. Histopathologic diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9650920" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diagnosis of Q fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23535757" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930423" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17482524" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The liver in brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23596444" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The schistosoma granuloma: friend or foe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26357627" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hepatobiliary Schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3410227" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hepatic fibrin-ring granulomas in visceral leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6696185" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pinworm granuloma of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15573907" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence of hepatic granulomas in chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15100526" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The prevalence of hepatic granulomas in chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2836298" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Epstein-Barr virus infection and hepatic fibrin-ring granulomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2820347" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : 'Ring' granulomas in cytomegalovirus hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30127039" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hepatic sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30947880" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sarcoidosis and the Liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20412710" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Wegener s granulomatosis with granulomatous liver involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27792061" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fibrin Ring Granulomas in Checkpoint Inhibitor-induced Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4689171" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Granulomatous hepatitis and prolonged fever of unknown origin: a study of 13 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5458036" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Isolated granulomas in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/912651" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Malignant lymphoma obscured by concomitant extensive epithelioid granulomas: report of three cases with similar clinicopathologic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/912651" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Malignant lymphoma obscured by concomitant extensive epithelioid granulomas: report of three cases with similar clinicopathologic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1921501" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Granulomatous hepatitis: a retrospective review of 88 cases at the Mayo Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20600067" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Abnormal liver enzymes in a patient with Crohn's disease, psoriatic arthritis, and recurrent pancreatitis. Answer to the clinical challenges and images in GI question: image 5: Idiopathic granulomatous hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28882937" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Granulomatous hepatitis in a patient with Crohn's disease and cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8854654" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Idiopathic granulomatous hepatitis manifested with fever of unknown origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2007749" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Granulomatous hepatitis and fever of unknown origin. An 11-year experience of 23 cases with three years' follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/203507" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Idiopathic granulomatous hepatitis with a prolonged course: effect of corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26134699" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Granulomatous hepatitis with hepatic mass lesions and a response to infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7887553" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Methotrexate treatment of idiopathic granulomatous hepatitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
